Drugs / 14N Nitrate
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03787082 | Dec 2022 → Dec 2023 | diastolic heart failure, pulmonary hypertension | Gladwin, Mark, MD | Withdrawn | No outcome recorded |
| Phase 1 | NCT02980068 | Aug 2017 → Feb 2022 | heart failure, pulmonary hypertension | Gladwin, Mark, MD | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 14N Nitrate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02980068 ↗ |
| Known as | 14N Sodium Nitrate | “Participants will receive a single dose of the study drug,:14N Sodium Nitrate(1000mg): standard sodium nitrate, and all will receive one dose of CLA 3g.” NCT03787082 ↗ |
| Route | Oral | “1,000 mg/11.18 mmol, oral, on day hour, hour zero” NCT02980068 ↗ |